Vinpocetine Renewal pills 5mg, 50pcs

Composition

1 tablet contains: Active ingredient: vinpocetine-0.005 gw auxiliary substances: lactose (milk sugar) – 0.17500 g colloidal silicon dioxide (aerosil) – 0.00125 g potato starch-0.06625 g zinc-0.00125 g magnesium stearate-0.00125 g

Pharmacological action

Improves brain metabolism by increasing the consumption of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia; facilitating the transport of oxygen and energy supply substrates to tissues (due to a decrease in the affinity of red blood cells for it, increased absorption and metabolism of glucose, and switching it to an energetically more favorable aerobic direction). Selectively blocks Ca2+ / dependent phosphodiesterase( PDE); increases the levels of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP) in the brain. Increases the concentration of ATP and the ratio of ATP/AMP in brain tissues; increases the exchange of norepinephrine and serotonin in the brain; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect.

Indications

• Neurology: symptomatic treatment of the consequences of ischemic stroke, vascular vertebrobasilar insufficiency, vascular dementia, cerebral vascular atherosclerosis, post-traumatic, hypertensive encephalopathy.
• Ophthalmology: chronic vascular diseases of the retina and choroid of the eye.
• Otology: perceptual hearing loss, Meniere’s disease, tinnitus sensation.

Contraindications

Acute phase of hemorrhagic stroke, severe form of ischemic heart disease, severe cardiac arrhythmias. Hypersensitivity to vinpocetine or other components of the drug. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption, because the drug contains lactose. Pregnancy, breast-feeding period. Children under 18 years of age (due to the lack of data from clinical studies). With caution, coronary heart disease (severe course), severe arrhythmias (parenteral use). In hemorrhagic stroke, parenteral use is possible only after the acute events subside (usually after 5-7 days).

Side effects

Data on side effects are presented by systemic organ classes according to the MedDRA classification and with the following frequency: infrequent (≥1/1000, <1/100); rare (≥1/10000, <1/1000); very rare (From the blood and lymphatic system: rarely-leukopenia, thrombocytopenia; very rarely-anemia, agglutination of red blood cells. Immune system disorders: very rare — hypersensitivity. From the side of metabolism and nutrition: infrequently-hypercholesterolemia; rarely-decreased appetite, anorexia, diabetes mellitus. Mental disorders: rarely-insomnia, sleep disorders, agitation, restlessness; very rarely-euphoria, depression. From the nervous system: infrequently-headache; rarely-dizziness, taste disorders, stupor, hemiparesis, drowsiness, amnesia; very rarely-tremor, spasms. From the side of the organ of vision: rarely-edema of the optic nerve disc; very rarely-conjunctival hyperemia. From the side of the organ of hearing and labyrinth: infrequently-vertigo; rarely-hyperacusis, hypoacusia, tinnitus. From the heart: rarely-ischemia/myocardial infarction, angina, bradycardia, tachycardia, extrasystoles, palpitation sensation; very rarely-arrhythmia, atrial fibrillation. Vascular disorders: infrequently-hypotension; rarely-hypertension, hot flashes, thrombophlebitis; very rarely-fluctuations in blood pressure. From the digestive system: infrequently-abdominal discomfort, dry mouth, nausea; rarely-abdominal pain, constipation, diarrhea, dyspepsia, vomiting; very rarely — dysphagia, stomatitis. From the skin and subcutaneous tissues: rarely-erythema, increased sweating, pruritus, urticaria, rash; very rarely-dermatitis. General disorders and disorders at the injection site: rarely-asthenia, increased fatigue, feeling of heat; very rarely-chest discomfort, hypothermia. Effects on the results of laboratory and instrumental studies: infrequently-a decrease in blood pressure; rarely-an increase in blood pressure, an increase in serum triglyceride concentration, ST segment depression on the ECG, a decrease/increase in the number of eosinophils, a change in the activity of liver enzymes; very rarely — an increase/decrease in the number of white blood cells, a decrease in the number of red blood cells, a reduction in thrombin time, an increase in body weight.

Interaction

It is possible to increase the antihypertensive effect when used simultaneously with methyldopa (blood pressure monitoring is necessary). Despite the lack of data confirming the possibility of interaction, caution is recommended when using concomitantly with central-acting drugs, antiarrhythmics and anticoagulants.

How to take, course of use and dosage

Inside, after a meal, the initial dose is 15 mg / day, the standard daily dose is 5-10 mg 2 times a day. The maximum daily dose is 30 mg. The course of treatment is 1-3 months.

Overdose

Treatment: gastric lavage, taking activated charcoal, symptomatic treatment.

Special instructions

In the case of initial prolongation of the Q-T interval, as well as when used simultaneously with drugs that extend the Q-T interval, periodic ECG monitoring is necessary during treatment with vinpocetine.

Shelf

life is 3 years.

Active ingredient

Vinpocetine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets